| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| H Silve. Fluvoxamine as an adjunctive agent in schizophrenia. CNS drug reviews. vol 7. issue 3. 2002-01-14. PMID:11607044. |
the balance of available evidence indicates that fluvoxamine can improve primary negative symptoms in chronic schizophrenia patients treated with typical antipsychotics and suggests that it may also do so in some patients treated with clozapine. |
2002-01-14 |
2023-08-12 |
Not clear |
| V Ozdemir, W Kalow, P Posner, E J Collins, J L Kennedy, B K Tang, L J Albers, C Reist, R Roy, W Walkes, P Afr. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia. Journal of clinical psychopharmacology. vol 21. issue 4. 2002-01-09. PMID:11476124. |
cyp1a2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia. |
2002-01-09 |
2023-08-12 |
Not clear |
| V Ozdemir, W Kalow, P Posner, E J Collins, J L Kennedy, B K Tang, L J Albers, C Reist, R Roy, W Walkes, P Afr. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia. Journal of clinical psychopharmacology. vol 21. issue 4. 2002-01-09. PMID:11476124. |
clozapine is an atypical antipsychotic drug and displays efficacy in 30% to 60% of patients with schizophrenia who do not respond to traditional antipsychotics. |
2002-01-09 |
2023-08-12 |
Not clear |
| V Ozdemir, W Kalow, P Posner, E J Collins, J L Kennedy, B K Tang, L J Albers, C Reist, R Roy, W Walkes, P Afr. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia. Journal of clinical psychopharmacology. vol 21. issue 4. 2002-01-09. PMID:11476124. |
patients with schizophrenia or schizoaffective disorder were prospectively monitored during clozapine treatment (n = 18). |
2002-01-09 |
2023-08-12 |
Not clear |
| J P Lindenmayer, J Volavka, J Lieberman, B Sheitman, L Citrome, M Chakos, P Czobor, B Parker, A Iskande. Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial. Journal of clinical psychopharmacology. vol 21. issue 4. 2002-01-09. PMID:11476131. |
this article presents an open-label, prospective, 14-week trial with olanzapine in patients with schizophrenia and schizoaffective disorder selected for unambiguous resistance to either clozapine or risperidone and to typical antipsychotics. |
2002-01-09 |
2023-08-12 |
Not clear |
| J H Lee, J I Woo, H Y Meltze. Effects of clozapine on sleep measures and sleep-associated changes in growth hormone and cortisol in patients with schizophrenia. Psychiatry research. vol 103. issue 2-3. 2002-01-03. PMID:11549404. |
effects of clozapine on sleep measures and sleep-associated changes in growth hormone and cortisol in patients with schizophrenia. |
2002-01-03 |
2023-08-12 |
human |
| M J Sernyak, R Rosenheck, R Desai, M Stolar, G Rippe. Impact of clozapine prescription on inpatient resource utilization. The Journal of nervous and mental disease. vol 189. issue 11. 2002-01-02. PMID:11758660. |
all patients who had clozapine initiated during an inpatient hospitalization within the va for schizophrenia over a 4-year period (n = 1415) were matched with a comparison group (n = 2,830) on key service utilization variables and other possible confounding demographic and clinical variables using propensity scoring-an accepted statistical method, although still relatively little used in psychiatry. |
2002-01-02 |
2023-08-12 |
Not clear |
| B C Lund, P J Perry, J M Brooks, S Arnd. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Archives of general psychiatry. vol 58. issue 12. 2001-12-28. PMID:11735847. |
clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. |
2001-12-28 |
2023-08-12 |
Not clear |
| B C Lund, P J Perry, J M Brooks, S Arnd. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Archives of general psychiatry. vol 58. issue 12. 2001-12-28. PMID:11735847. |
numerous case reports have linked clozapine to the development of diabetes mellitus and hyperlipidemia in patients with schizophrenia. |
2001-12-28 |
2023-08-12 |
Not clear |
| M Mueck-Weymann, J Acker, M W Agelin. Autonomic responses of blood vessels and sweat glands in patients with schizophrenia treated with olanzapine or clozapine. Psychopharmacology. vol 157. issue 4. 2001-12-19. PMID:11605095. |
autonomic responses of blood vessels and sweat glands in patients with schizophrenia treated with olanzapine or clozapine. |
2001-12-19 |
2023-08-12 |
Not clear |
| L Citrome, J Volavka, P Czobor, B Sheitman, J P Lindenmayer, J McEvoy, T B Cooper, M Chakos, J A Lieberma. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatric services (Washington, D.C.). vol 52. issue 11. 2001-12-14. PMID:11684748. |
effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. |
2001-12-14 |
2023-08-12 |
Not clear |
| E C Tan, S A Chong, R Mahendran, F Dong, C H Ta. Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor. Biological psychiatry. vol 50. issue 2. 2001-12-10. PMID:11526996. |
case-control association studies have identified the t102c polymorphism of the 5-ht2a receptor gene as being associated with schizophrenia and responsiveness to clozapine. |
2001-12-10 |
2023-08-12 |
Not clear |
| I Murad, I Kremer, M Dobrusin, M Muhaheed, I Bannoura, D J Müller, T G Schulze, A Reshef, M Blanaru, S Gathas, V Tsenter, M Rietschel, R H Belmaker, W Maier, R P Ebstei. A family-based study of the Cys23Ser 5HT2C serotonin receptor polymorphism in schizophrenia. American journal of medical genetics. vol 105. issue 3. 2001-12-04. PMID:11353441. |
the 5ht2c receptor has a high affinity for clozapine, a nontypical neuroleptic, and has therefore been postulated to play a role in mediating negative symptoms and neuroleptic response in schizophrenia. |
2001-12-04 |
2023-08-12 |
Not clear |
| E F Cheun. Obsessive-compulsive symptoms during treatment with clozapine in a patient with schizophrenia. The Australian and New Zealand journal of psychiatry. vol 35. issue 5. 2001-12-04. PMID:11551293. |
obsessive-compulsive symptoms during treatment with clozapine in a patient with schizophrenia. |
2001-12-04 |
2023-08-12 |
Not clear |
| J R Bustillo, J Lauriello, L M Rowland, R E Jung, H Petropoulos, B L Hart, J Blanchard, S J Keith, W M Brook. Effects of chronic haloperidol and clozapine treatments on frontal and caudate neurochemistry in schizophrenia. Psychiatry research. vol 107. issue 3. 2001-12-04. PMID:11566430. |
effects of chronic haloperidol and clozapine treatments on frontal and caudate neurochemistry in schizophrenia. |
2001-12-04 |
2023-08-12 |
Not clear |
| I Gaertner, H J Gaertner, R Vonthein, K Diet. Therapeutic drug monitoring of clozapine in relapse prevention: a five-year prospective study. Journal of clinical psychopharmacology. vol 21. issue 3. 2001-11-01. PMID:11386494. |
twenty-three outpatients with schizophrenia (icd-10 f20.xx) treated with clozapine (cz) as monotherapy entered a prospective study on relapse prevention. |
2001-11-01 |
2023-08-12 |
Not clear |
| F E Scheepers, C C Gispen-de Wied, H G Westenberg, R S Kah. The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 25. issue 4. 2001-11-01. PMID:11557160. |
the mechanism of action of both typical antipsychotics and the atypical antipsychotic, clozapine, may be related to the (changing) interaction of dopamine and serotonin in schizophrenia. |
2001-11-01 |
2023-08-12 |
Not clear |
| J M Kane, S R Marder, N R Schooler, W C Wirshing, D Umbricht, R W Baker, D A Wirshing, A Safferman, R Ganguli, M McMeniman, M Borenstei. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Archives of general psychiatry. vol 58. issue 10. 2001-11-01. PMID:11576036. |
clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. |
2001-11-01 |
2023-08-12 |
Not clear |
| D C Henderso. Clozapine: diabetes mellitus, weight gain, and lipid abnormalities. The Journal of clinical psychiatry. vol 62 Suppl 23. 2001-11-01. PMID:11603884. |
clozapine remains the most effective agent for treatment-resistant patients with schizophrenia. |
2001-11-01 |
2023-08-12 |
Not clear |
| D C Henderso. Clozapine: diabetes mellitus, weight gain, and lipid abnormalities. The Journal of clinical psychiatry. vol 62 Suppl 23. 2001-11-01. PMID:11603884. |
despite the potential risks of medical morbidities, clozapine continues to have a major role in the care of treatment-resistant patients with schizophrenia. |
2001-11-01 |
2023-08-12 |
Not clear |